UKI NETS

UK and Ireland Neuroendocrine Tumour Society

Become a member?

Join Now

Members’ Area

Log In

Search

About UKI NETS
Membership
News & Events
Clinical Practice
- ENETS Guidelines
Research
NETs for Newcomers
- Faculty Members
- Educational Event Endorsement
Nurses and Allied Health Professionals
- ENETS Nurse Group
Patient Advocacy
Contact

About UKI NETS
Membership
News & Events
Clinical Practice
- ENETS Guidelines
Research
NETs for Newcomers
- Faculty Members
- Educational Event Endorsement
Nurses and Allied Health Professionals
- ENETS Nurse Group
Patient Advocacy
Contact

12 January 2021

Temozolomide Alone or Combined with Capecitabine for the Treatment of Advanced Pancreatic Neuroendocrine Tumor.

« Perspectives of patients and physicians about neuroendocrine tumors. A qualitative study
Assessment of Therapy-Related Myeloid Neoplasms in Patients With Neuroendocrine Tumors After Peptide Receptor Radionuclide Therapy- A Systematic Review. »

Recent News

UKINETS Spring Newsletter available now
Launching the new NET App, developed by UKINETS and NCUK
Cancer registry data on NETs
Please take part in our Survey of Dietetic Practice in Neuroendocrine Tumours across the UK & Ireland
BNMS Virtual Spring Meeting 2021

Sign up for our newsletter

Sign-up for our email newsletter. Simply give us your email address in the box below to sign-up.

Email

Links

Disclaimer & Copyright
Privacy Policy

Friends of UKI NETS

NET Cancer Day
RCF
NET Patient Foundation
ENETS
AMEND
Cancer 52

Details

© 2016 UKI NETS
Do not reproduce without permission
Thanks to our design agency Dusted

Address

UK & Ireland Neuroendocrine Tumour Society Company limited by guarantee. Registered in England & Wales. Company number 6672185 Registered office address: Athenia House, 10-14 Andover Road, Winchester, Hampshire, England, SO23 7BS. The UK and Ireland Neuroendocrine Tumour Society was registered with the Charity Commission on 16 July 2012, charity registration number 1148145.